We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Correction |

Errors in Abstract, Affiliations, and Conclusions FREE

Arch Dermatol. 2001;137(8):1112. doi:10-1001/pubs.Arch Dermatol.-ISSN-0003-987x-137-8-dcx10001.
Text Size: A A A
Published online

In the review by Yosipovitch et al titled "Suggested Rationale for Prevention and Treatment of Glucocorticoid-Induced Bone Loss in Dermatologic Patients," published in the April issue of the ARCHIVES (2001;137:477-481), some errors occurred on pages 477 and 479-481.

On page 477, the first paragraph of the introduction of the main text beginning with "We recommend that patients who are receiving a long-term regimen of corticosteroids be managed with a 3-pronged approach. . . . " should have been the last paragraph of the abstract. The author listed in the byline as Goh Chee Leok, MD, should have read Chee Leok Goh, MD, and the authors' affiliations should have read, "From the National Skin Center, Singapore (Drs Yosipovitch, Hoon, and Goh)."

On page 479, in the last sentence of the first paragraph, "hyperkalemic" should have been spelled "hypercalcemic."

On pages 480 and 481, the guidelines in the "Conclusions" section should have read as follows:

Risk Assessment:

  • Baseline lumbar spine and femoral neck bone mineral density assessment (DXA testing) at the beginning of therapy and twice annually thereafter.

  • In patients 60 years of age or older, a yearly radiography assessment of the spine to exclude fractures.


  • Weight-bearing and non–weight-bearing exercises and physical therapy.

  • Refraining from smoking and excessive alcohol consumption.

  • Administration of 800 IU/d of vitamin D, plus 1000 mg/d of calcium, on commencing high-dose, long-term glucocorticoid treatment, excluding those with hypercalcemia, hypercalciuria, and/or nephrolithiasis.

  • Women with early and late menopause receiving high-dose, long-term glucocorticosteroid treatment should be given 0.625-1.25 mg/d of conjugated estrogen or 50 µg/d of transdermal estradiol, alone or with progestogen preparations.

  • Patients who have osteopenia defined as T scores below −1 at the beginning of systemic glucocorticoid treatment and patients with accelerated bone loss during the first 6 to 12 months of treatment may be considered for treatment with a bisphosphonate (eg, 5 mg/d of alendronate, 5 mg/d of risedronate, or 400 mg/d of cyclical etidronate).


  • In patients with bone densities more than 2.5 SDs below the young normal mean (T score less than −2.5) or in those patients with previous osteoporotic fractures or significant osteoporosis on radiography, the addition of a bisphosphonate should include 10 mg/d of alendronate (approved by the Food and Drug Administration for patients receiving prolonged glucocorticoid therapy), 5 mg/d of risedronate, or 400 mg/d of cyclical etidronate. Patients with severe osteoporosis, especially those with symptoms and fractures, may add 200 IU/d of nasal calcitonin to their regimen.

  • Postmenopausal women with low bone density should be given 60 mg/d of raloxifene hydrochloride.


  • Yearly assessment of serum blood and urine calcium excretion and alkaline phosphatase levels.

  • Referral to a rheumatologist or endocrinologist specializing in the treatment of osteoporosis for assessment and long-term management.





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Related Content

Customize your page view by dragging & repositioning the boxes below.